Abstract

Malignancy as an etiological factor involved in priapism pathogenesis is rare. Malignant priapism (MP) can arise as a result of penile tumor invasion, either from primary penile tumors or from metastatic penile tumors, or due to hematological malignancies. Non-urological penile metastases are associated with significant worse prognosis compared to urological penile metastases, the appearance of priapism in such cases affecting even more the prognosis and the survival of these patients. Patients diagnosed with hematological malignancies and priapism present significant higher survival rates compared to those who develop MP in the context of a non-hematological malignancy, this being related to the fact that hematological malignancies are more sensitive to chemo- and radiotherapy. Most malignant priapism cases are ischemic; therefore the management should be based on the initial steps of the IP therapeutic protocol. Considering the trigger factor that has led to the priapic event specific oncologic treatment can be added as well.

MeSH

Prognosis, Hematologic Neoplasms, Neoplasm Metastasis, Therapeutics, Priapism

Cited by

• Updates in the use of radiotherapy in the management of primary and locally-advanced penile cancer. Asian J Urol, 2022
• Malignant priapism: case report and update on management protocols. Transl Androl Urol, 2023
• The value of leukapheresis for treatment of priapism as presenting feature of chronic myeloid leukemia-Case report and review of literature. EJHaem, 2022
• Priapism in a Patient with Rectal Adenocarcinoma. Diseases, 2023
• A Case of Malignant Priapism Secondary to Muscle Invasive Bladder Cancer and Review of Palliative Management. Case Rep Urol, 2025
• The Current Challenges in Diagnosing and Treating Malignant Priapism: A Comprehensive Review. Urol Res Pract, 2023